Cargando…
β-Glucuronidase Pattern Predicted From Gut Metagenomes Indicates Potentially Diversified Pharmacomicrobiomics
β-glucuronidases (GUS) of intestinal bacteria remove glucuronic acid from glucoronides, reversing phase II metabolism of the liver and affecting the level of active deconjugated metabolites deriving from drugs or xenobiotics. Two hundred seventy-nine non-redundant GUS sequences are known in the gut...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928169/ https://www.ncbi.nlm.nih.gov/pubmed/35308380 http://dx.doi.org/10.3389/fmicb.2022.826994 |
_version_ | 1784670593728118784 |
---|---|
author | Candeliere, Francesco Raimondi, Stefano Ranieri, Raffaella Musmeci, Eliana Zambon, Alfonso Amaretti, Alberto Rossi, Maddalena |
author_facet | Candeliere, Francesco Raimondi, Stefano Ranieri, Raffaella Musmeci, Eliana Zambon, Alfonso Amaretti, Alberto Rossi, Maddalena |
author_sort | Candeliere, Francesco |
collection | PubMed |
description | β-glucuronidases (GUS) of intestinal bacteria remove glucuronic acid from glucoronides, reversing phase II metabolism of the liver and affecting the level of active deconjugated metabolites deriving from drugs or xenobiotics. Two hundred seventy-nine non-redundant GUS sequences are known in the gut microbiota, classified in seven structural categories (NL, L1, L2, mL1, mL2, mL1,2, and NC) with different biocatalytic properties. In the present study, the intestinal metagenome of 60 healthy subjects from five geographically different cohorts was assembled, binned, and mined to determine qualitative and quantitative differences in GUS profile, potentially affecting response to drugs and xenobiotics. Each metagenome harbored 4–70 different GUS, altogether accounting for 218. The amount of intestinal bacteria with at least one GUS gene was highly variable, from 0.7 to 82.2%, 25.7% on average. No significant difference among cohorts could be identified, except for the Ethiopia (ETH) cohort where GUS-encoding bacteria were significantly less abundant. The structural categories were differently distributed among the metagenomes, but without any statistical significance related to the cohorts. GUS profiles were generally dominated by the category NL, followed by mL1, L2, and L1. The GUS categories most involved in the hydrolysis of small molecules, including drugs, are L1 and mL1. Bacteria contributing to these categories belonged to Bacteroides ovatus, Bacteroides dorei, Bacteroides fragilis, Escherichia coli, Eubacterium eligens, Faecalibacterium prausnitzii, Parabacteroides merdae, and Ruminococcus gnavus. Bacteria harboring L1 GUS were generally scarcely abundant (<1.3%), except in three metagenomes, where they reached up to 24.3% for the contribution of E. coli and F. prausnitzii. Bacteria harboring mL1 GUS were significantly more abundant (mean = 4.6%), with Bacteroides representing a major contributor. Albeit mL1 enzymes are less active than L1 ones, Bacteroides likely plays a pivotal role in the deglucuronidation, due to its remarkable abundance in the microbiomes. The observed broad interindividual heterogeneity of GUS profiles, particularly of the L1 and mL1 categories, likely represent a major driver of pharmacomicrobiomics variability, affecting drug response and toxicity. Different geographical origins, genetic, nutritional, and lifestyle features of the hosts seemed not to be relevant in the definition of glucuronidase activity, albeit they influenced the richness of the GUS profile. |
format | Online Article Text |
id | pubmed-8928169 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-89281692022-03-18 β-Glucuronidase Pattern Predicted From Gut Metagenomes Indicates Potentially Diversified Pharmacomicrobiomics Candeliere, Francesco Raimondi, Stefano Ranieri, Raffaella Musmeci, Eliana Zambon, Alfonso Amaretti, Alberto Rossi, Maddalena Front Microbiol Microbiology β-glucuronidases (GUS) of intestinal bacteria remove glucuronic acid from glucoronides, reversing phase II metabolism of the liver and affecting the level of active deconjugated metabolites deriving from drugs or xenobiotics. Two hundred seventy-nine non-redundant GUS sequences are known in the gut microbiota, classified in seven structural categories (NL, L1, L2, mL1, mL2, mL1,2, and NC) with different biocatalytic properties. In the present study, the intestinal metagenome of 60 healthy subjects from five geographically different cohorts was assembled, binned, and mined to determine qualitative and quantitative differences in GUS profile, potentially affecting response to drugs and xenobiotics. Each metagenome harbored 4–70 different GUS, altogether accounting for 218. The amount of intestinal bacteria with at least one GUS gene was highly variable, from 0.7 to 82.2%, 25.7% on average. No significant difference among cohorts could be identified, except for the Ethiopia (ETH) cohort where GUS-encoding bacteria were significantly less abundant. The structural categories were differently distributed among the metagenomes, but without any statistical significance related to the cohorts. GUS profiles were generally dominated by the category NL, followed by mL1, L2, and L1. The GUS categories most involved in the hydrolysis of small molecules, including drugs, are L1 and mL1. Bacteria contributing to these categories belonged to Bacteroides ovatus, Bacteroides dorei, Bacteroides fragilis, Escherichia coli, Eubacterium eligens, Faecalibacterium prausnitzii, Parabacteroides merdae, and Ruminococcus gnavus. Bacteria harboring L1 GUS were generally scarcely abundant (<1.3%), except in three metagenomes, where they reached up to 24.3% for the contribution of E. coli and F. prausnitzii. Bacteria harboring mL1 GUS were significantly more abundant (mean = 4.6%), with Bacteroides representing a major contributor. Albeit mL1 enzymes are less active than L1 ones, Bacteroides likely plays a pivotal role in the deglucuronidation, due to its remarkable abundance in the microbiomes. The observed broad interindividual heterogeneity of GUS profiles, particularly of the L1 and mL1 categories, likely represent a major driver of pharmacomicrobiomics variability, affecting drug response and toxicity. Different geographical origins, genetic, nutritional, and lifestyle features of the hosts seemed not to be relevant in the definition of glucuronidase activity, albeit they influenced the richness of the GUS profile. Frontiers Media S.A. 2022-03-03 /pmc/articles/PMC8928169/ /pubmed/35308380 http://dx.doi.org/10.3389/fmicb.2022.826994 Text en Copyright © 2022 Candeliere, Raimondi, Ranieri, Musmeci, Zambon, Amaretti and Rossi. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Microbiology Candeliere, Francesco Raimondi, Stefano Ranieri, Raffaella Musmeci, Eliana Zambon, Alfonso Amaretti, Alberto Rossi, Maddalena β-Glucuronidase Pattern Predicted From Gut Metagenomes Indicates Potentially Diversified Pharmacomicrobiomics |
title | β-Glucuronidase Pattern Predicted From Gut Metagenomes Indicates Potentially Diversified Pharmacomicrobiomics |
title_full | β-Glucuronidase Pattern Predicted From Gut Metagenomes Indicates Potentially Diversified Pharmacomicrobiomics |
title_fullStr | β-Glucuronidase Pattern Predicted From Gut Metagenomes Indicates Potentially Diversified Pharmacomicrobiomics |
title_full_unstemmed | β-Glucuronidase Pattern Predicted From Gut Metagenomes Indicates Potentially Diversified Pharmacomicrobiomics |
title_short | β-Glucuronidase Pattern Predicted From Gut Metagenomes Indicates Potentially Diversified Pharmacomicrobiomics |
title_sort | β-glucuronidase pattern predicted from gut metagenomes indicates potentially diversified pharmacomicrobiomics |
topic | Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928169/ https://www.ncbi.nlm.nih.gov/pubmed/35308380 http://dx.doi.org/10.3389/fmicb.2022.826994 |
work_keys_str_mv | AT candelierefrancesco bglucuronidasepatternpredictedfromgutmetagenomesindicatespotentiallydiversifiedpharmacomicrobiomics AT raimondistefano bglucuronidasepatternpredictedfromgutmetagenomesindicatespotentiallydiversifiedpharmacomicrobiomics AT ranieriraffaella bglucuronidasepatternpredictedfromgutmetagenomesindicatespotentiallydiversifiedpharmacomicrobiomics AT musmecieliana bglucuronidasepatternpredictedfromgutmetagenomesindicatespotentiallydiversifiedpharmacomicrobiomics AT zambonalfonso bglucuronidasepatternpredictedfromgutmetagenomesindicatespotentiallydiversifiedpharmacomicrobiomics AT amarettialberto bglucuronidasepatternpredictedfromgutmetagenomesindicatespotentiallydiversifiedpharmacomicrobiomics AT rossimaddalena bglucuronidasepatternpredictedfromgutmetagenomesindicatespotentiallydiversifiedpharmacomicrobiomics |